BioSpace News Archive

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI) from March 2, 2017, through February 22, 2019 (the “Class Period”).

Cipla USA Inc. (“Cipla USA”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”), announced the acquisition of the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. (“Achaogen”) in a Chapter 11, U.S. Bankruptcy Code auction of Achaogen’s assets

Healthcare organizations are widely evaluating and pursuing digital technologies to strengthen consumer relationships and experiences

PRA Health Sciences, Inc. (NASDAQ: PRAH, “PRA”) announced the buyout of its joint venture with Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) in Japan, which was completed on June 1.

The Honourable Ginette Petitpas Taylor, Canada’s Minister of Health, will be in Sudbury to highlight recent Government of Canada initiatives related to paediatric drugs.

ASPCA fleet of mobile and stationary spay/neuter clinics provides high-quality, low-cost surgery to tens of thousands of pet owners and rescue groups each year

REGENXBIO Inc. (Nasdaq: RGNX), today announced an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an expansion of its pipeline to include novel treatments for hereditary angioedema (HAE) and neurodegenerative diseases, including tauopathies, using NAV Vectors to deliver therapeutic antibodies.

Varian, Inc.(NYSE: VAR) today announced its third quarter fiscal year 2019 results.

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today reported financial results for the second quarter ended June 30, 2019, and provided an update on its business progress in the period.